Cargando…
Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382667/ https://www.ncbi.nlm.nih.gov/pubmed/30685251 http://dx.doi.org/10.1016/j.vaccine.2019.01.027 |
_version_ | 1783396687918661632 |
---|---|
author | Coelho, Camila H. Gazzinelli-Guimaraes, Pedro Henrique Howard, Jennifer Barnafo, Emma Alani, Nada A.H. Muratova, Olga McCormack, Ashley Kelnhofer, Emily Urban, Joseph F. Narum, David L. Anderson, Charles Langhorne, Jean Nutman, Thomas B. Duffy, Patrick E. |
author_facet | Coelho, Camila H. Gazzinelli-Guimaraes, Pedro Henrique Howard, Jennifer Barnafo, Emma Alani, Nada A.H. Muratova, Olga McCormack, Ashley Kelnhofer, Emily Urban, Joseph F. Narum, David L. Anderson, Charles Langhorne, Jean Nutman, Thomas B. Duffy, Patrick E. |
author_sort | Coelho, Camila H. |
collection | PubMed |
description | INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection. METHODS: Using an experimental murine model for a chronic helminth infection (Heligmosomoides polygyrus bakeri - Hpb), we evaluated whether prior infection alters the activity of Pfs230D1-EPA/Alhydrogel® TBV in mice. RESULTS: After establishment of a chronic infection, characterized by a marked increase of parasite antigen-specific IgG1, IgA and IgE antibody responses, concomitant with an increase of systemic IL-10, IL-5 and IL-6 levels, the Hpb-infected mice were immunized with Pfs230D1-EPA/Alhydrogel® and the vaccine-specific immune response was compared with that in non-infected immunized mice. TBV immunizations induced an elevated vaccine specific-antibody response, however Pfs230D1 specific-IgG levels were similar between infected and uninfected mice at days 15, 25 and 35 post-vaccination. Absolute numbers of Pfs230D1-activated B cells generated in response to the vaccine were also similar among the vaccinated groups. Finally, vaccine activity assessed by reduction of oocyst number in P. falciparum infected mosquitoes was similar between Hpb-infected and immunized mice with non-infected immunized mice. CONCLUSION: Pfs230D1-EPA/Alhydrogel® efficacy is not impaired by a chronic helminth infection in mice. |
format | Online Article Text |
id | pubmed-6382667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-63826672019-03-01 Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice Coelho, Camila H. Gazzinelli-Guimaraes, Pedro Henrique Howard, Jennifer Barnafo, Emma Alani, Nada A.H. Muratova, Olga McCormack, Ashley Kelnhofer, Emily Urban, Joseph F. Narum, David L. Anderson, Charles Langhorne, Jean Nutman, Thomas B. Duffy, Patrick E. Vaccine Article INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection. METHODS: Using an experimental murine model for a chronic helminth infection (Heligmosomoides polygyrus bakeri - Hpb), we evaluated whether prior infection alters the activity of Pfs230D1-EPA/Alhydrogel® TBV in mice. RESULTS: After establishment of a chronic infection, characterized by a marked increase of parasite antigen-specific IgG1, IgA and IgE antibody responses, concomitant with an increase of systemic IL-10, IL-5 and IL-6 levels, the Hpb-infected mice were immunized with Pfs230D1-EPA/Alhydrogel® and the vaccine-specific immune response was compared with that in non-infected immunized mice. TBV immunizations induced an elevated vaccine specific-antibody response, however Pfs230D1 specific-IgG levels were similar between infected and uninfected mice at days 15, 25 and 35 post-vaccination. Absolute numbers of Pfs230D1-activated B cells generated in response to the vaccine were also similar among the vaccinated groups. Finally, vaccine activity assessed by reduction of oocyst number in P. falciparum infected mosquitoes was similar between Hpb-infected and immunized mice with non-infected immunized mice. CONCLUSION: Pfs230D1-EPA/Alhydrogel® efficacy is not impaired by a chronic helminth infection in mice. Elsevier Science 2019-02-14 /pmc/articles/PMC6382667/ /pubmed/30685251 http://dx.doi.org/10.1016/j.vaccine.2019.01.027 Text en http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Coelho, Camila H. Gazzinelli-Guimaraes, Pedro Henrique Howard, Jennifer Barnafo, Emma Alani, Nada A.H. Muratova, Olga McCormack, Ashley Kelnhofer, Emily Urban, Joseph F. Narum, David L. Anderson, Charles Langhorne, Jean Nutman, Thomas B. Duffy, Patrick E. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice |
title | Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice |
title_full | Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice |
title_fullStr | Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice |
title_full_unstemmed | Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice |
title_short | Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice |
title_sort | chronic helminth infection does not impair immune response to malaria transmission blocking vaccine pfs230d1-epa/alhydrogel® in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382667/ https://www.ncbi.nlm.nih.gov/pubmed/30685251 http://dx.doi.org/10.1016/j.vaccine.2019.01.027 |
work_keys_str_mv | AT coelhocamilah chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT gazzinelliguimaraespedrohenrique chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT howardjennifer chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT barnafoemma chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT alaninadaah chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT muratovaolga chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT mccormackashley chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT kelnhoferemily chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT urbanjosephf chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT narumdavidl chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT andersoncharles chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT langhornejean chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT nutmanthomasb chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice AT duffypatricke chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice |